Clinical Trials
3 trialsNCT05665738 2026-06-05
Two-fraction HDR Monotherapy for Localized Prostate Cancer
University of California, San Francisco
Phase NA Recruiting
NCT06499870 2026-06-05
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT03274687 2026-05-20
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed